U.S. markets closed
  • S&P 500

    +30.98 (+0.74%)
  • Dow 30

    +229.23 (+0.66%)
  • Nasdaq

    +119.39 (+0.88%)
  • Russell 2000

    +30.21 (+1.35%)
  • Crude Oil

    +0.11 (+0.17%)
  • Gold

    +16.30 (+0.90%)
  • Silver

    +0.09 (+0.32%)

    +0.0098 (+0.82%)
  • 10-Yr Bond

    +0.0160 (+1.02%)

    +0.0098 (+0.70%)

    -0.5450 (-0.50%)

    +779.72 (+1.34%)
  • CMC Crypto 200

    +44.28 (+3.08%)
  • FTSE 100

    +53.54 (+0.76%)
  • Nikkei 225

    +26.45 (+0.09%)

Emerging Markets Report: At the Center of the Hemp Revolution

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ORLANDO, FL / ACCESSWIRE / January 23, 2019 / Yesterday, Digipath Inc. (DIGP) broke news that they were going to open their proprietary potency-testing laboratories in North Carolina, Oregon, and Arizona at hemp production sites owned by Hemp, Inc.

In a cannabis world where hemp has now been given a legitimate seat at a massive table, Digipath's expansion is notable. It is important to note that a venerable player like Hemp, Inc. - which could go with anyone in the marketplace - chose Digipath as its testing provider. Digipath will also have the lucrative opportunity to reach out to other hemp farmers in the areas where Hemp Inc. currently has processing centers.

And most importantly, it shows even more penetration and progress for Digipath, which after cutting its teeth in the rapidly expanding Nevada market, will including the Hemp deal, have a presence in four states in 2019… Nevada, California, North Carolina, Oregon and Arizona.

Remember, our sister publication Small Cap Sentinel commented on Digipath's stated interest in Colombia last week which many believe will be one of the top cannabis producers in the world in short order. (Moreon that here. )

While time will tell as to the potential economic benefits to Digipath and its shareholders, adding operations in expanding markets and leveraging the savings of already proven technology is normally good for the proforma. Ultimately, Qs and K's will tell that story too.

But what is becoming quite obvious is that Digipath's years of refining their testing practices and operational team to create a durable template that can be replicated just about anywhere where hemp is sewn and grown gives the company the ability to participate in a significant way in the Hemp Revolution. Nearly every legal cannabis location requires similar state regulated testing that Digipath provides.

For an Investor's Introduction to Digipath please visit https://bit.ly/2ALNzRR

About Digipath, Inc. & Digipath Labs, Inc.

Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry.Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.

About Emerging Markets Report

Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation,as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies. EMC has been paid 20,000 by Digipath for various marketing services including this report. EMC does not independently verify any of the content linked-to fromthis editorial. A contributor to this report holds 400,000 shares and receives $3,500 a month for a period of six months for investor relations services on the behalf of Digipath.



Emerging Markets Consulting, LLC
E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com

SOURCE: Emerging Markets Consulting, LLC